Literature DB >> 26671484

Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion.

Lili Meng1, Jizong Lin2, Libin Chen1, Zhenhua Wang1, Meilan Liu1, Yukun Liu1, Xin Chen1, Liqiong Zhu1, Hui Chen3, Jianping Zhang4.   

Abstract

AIM: Abnormal natural killer (NK) cell activity has been suggested to be a high-risk factor associated with unexplained recurrent spontaneous abortion (URSA). Intralipid, like immunoglobulin, is able to lower the activity of NK cells, which has been reported to be useful for improving URSA outcomes in pregnancy. This study aimed to determine whether intralipid could be used as an alternative treatment to intravenous immunoglobulin (IVIG) which is expensive and has many side-effects.
METHODS: A prospective, randomized clinical trial was conducted from December 2010 to December 2012. Eligible participants were matched and sorted randomly into the intralipid and the IVIG group. The primary outcome was the rate of successful pregnancy. In addition, comparisons of peripheral NK cell activities were accessed by flow cytometry. Moreover, the effects of intralipid on trophoblasts were investigated using a Matrigel assay with the JEG-3 cell line.
RESULTS: Seventy-six patients in the intralipid group and 78 in the IVIG group completed the trial. There were no statistically significant differences in successful pregnancy rates between the two groups (92.1 vs 88.2 %, P = 0.415). The reduced NK cell concentrations revealed the cytotoxic effects of the treatments in both groups. The invasive ability of JEG-3 cells was inhibited during co-culture with patient PBMCs. However, the inhibitory effect could be alleviated if the patient PBMCs were stimulated with intralipid.
CONCLUSIONS: Intralipid can be used as an alternative treatment to IVIG for URSA, and its potential mechanism of action may occur by regulating NK cell function and promoting trophoblast invasion.

Entities:  

Keywords:  Cell invasion; Intralipid; NK cells; Unexplained recurrent spontaneous abortion

Mesh:

Substances:

Year:  2015        PMID: 26671484     DOI: 10.1007/s00404-015-3922-8

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  9 in total

1.  Outcomes of Empirical Treatment With Intravenous Immunoglobulin G Combined With Low-Dose Aspirin in Women With Unexplained Recurrent Pregnancy Loss.

Authors:  Ju Hee Kim; Sung Hoon Kim; Nuri Yang; Yuri Ko; Sa Ra Lee; Hee Dong Chae
Journal:  J Korean Med Sci       Date:  2022-06-27       Impact factor: 5.354

2.  Effect of Intralipid infusion on peripheral blood T cells and plasma cytokines in women undergoing assisted reproduction treatment.

Authors:  Kerrie L Foyle; David J Sharkey; Lachlan M Moldenhauer; Ella S Green; Jasmine J Wilson; Cassandra J Roccisano; M Louise Hull; Kelton P Tremellen; Sarah A Robertson
Journal:  Clin Transl Immunology       Date:  2021-08-12

Review 3.  Recent Advances in Treatment of Recurrent Spontaneous Abortion.

Authors:  Tianqing Deng; Xiaoyang Liao; Shaomi Zhu
Journal:  Obstet Gynecol Surv       Date:  2022-06       Impact factor: 3.015

4.  Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.

Authors:  Aleena M Wojcieszek; Emily Shepherd; Philippa Middleton; Zohra S Lassi; Trish Wilson; Margaret M Murphy; Alexander Ep Heazell; David A Ellwood; Robert M Silver; Vicki Flenady
Journal:  Cochrane Database Syst Rev       Date:  2018-12-17

Review 5.  Recurrent pregnancy loss: current perspectives.

Authors:  Hady El Hachem; Vincent Crepaux; Pascale May-Panloup; Philippe Descamps; Guillaume Legendre; Pierre-Emmanuel Bouet
Journal:  Int J Womens Health       Date:  2017-05-17

6.  Recombinant human granulocyte- colony stimulating factor in women with unexplained recurrent pregnancy losses: a randomized clinical trial.

Authors:  A Eapen; M Joing; P Kwon; J Tong; E Maneta; C De Santo; F Mussai; D Lissauer; D Carter
Journal:  Hum Reprod       Date:  2019-03-01       Impact factor: 6.918

7.  Gestational and perinatal outcomes in recurrent miscarriages couples treated with lymphocyte immunotherapy.

Authors:  Manoel Sarno; Marcelo Borges Cavalcante; Marla Niag; Kleber Pimentel; Ivana Luz; Bianca Figueiredo; Tatiana Michelon; Jorge Neumann; Simone Lima; Isabela Nelly Machado; Edward Araujo Júnior; Ricardo Barini
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-07

8.  Recurrent Miscarriage: Diagnostic and Therapeutic Procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050).

Authors:  Bettina Toth; Wolfgang Würfel; Michael Bohlmann; Johannes Zschocke; Sabine Rudnik-Schöneborn; Frank Nawroth; Ekkehard Schleußner; Nina Rogenhofer; Tewes Wischmann; Michael von Wolff; Katharina Hancke; Sören von Otte; Ruben Kuon; Katharina Feil; Clemens Tempfer
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-04-27       Impact factor: 2.915

9.  Intralipid therapy and adverse reproductive outcome: is there any evidence?

Authors:  Parijot Kumar; Kevin Marron; Conor Harrity
Journal:  Reprod Fertil       Date:  2021-06-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.